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Abstract 
 
Little is known about the epidemiological and mortality patterns of systemic 
lupus erythematosus (SLE) in Africa. Aims of this study- to determine the 
demographics, clinical features and causes and predictors death in patients 
attending the Lupus clinic at the Chris Hani Baragwanath hospital in 
Soweto. Methods- the records of 226 patients who fulfilled American 
College of Rheumatism criteria for the diagnosis of SLE were reviewed.  
The mean (± SD) age at presentation was 34  (± 12.5) years. The female to 
male ratio was 18:1. The commonest clinical feature found was arthritis in 
70.4% of patients. Nephritis was present in 43.8% and CNS lupus in 15.9% 
of patients. 55 patients in this group had died and 64 were lost to follow up. 
The 5-year survival was 57% uncensored and 72% if censored for loss to 
follow up.  Infection (32.7%) was the commonest cause of death followed 
by renal failure (16.4%). Nephritis, CNS lupus and hypocomplementaemia 
were associated with mortality on univariate analysis. Lupus nephritis was 
the only independant predictor of mortality on multivariate analysis. 
Conclusion- this study confirms the poor outcome of SLE in the developing 
world and demonstrates that renal disease is a factor commonly implicated 
in mortality.  The 5-year survival and pattern of mortality is similar to that 
reported elsewhere in the developing world. 
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1.Introduction 
 
1.1 Background and history 
Systemic lupus erythematosus (SLE) is a multi-system autoimmune disorder 
caused by tissue damage resulting from antibody and complement-fixing 
immune complex deposition (Wallace and Hahn, 2002). The disease is the 
result of a complex interplay between genetic factors, hormones, 
autoantibodies and environmental factors (Isenberg, 1997). It is 
characterized by immunologically mediated, clinical and serological 
phenomena. It may resemble any of a variety of infectious, inflammatory, 
nutritional, malignant and metabolic disorders.  
 
‘Lupus’ which means wolf in Latin was probably first used by Hebernus of 
Tours in the tenth century to describe a skin lesion (Smith and Cyr, 1988). 
Because of the preponderance of cutaneous manifestations and the high 
prevalence of tuberculosis (TB) at the time, some of the earlier descriptions 
of the disease were attributed to cutaneous TB (Wallace and Hahn, 2002). 
Biett and Cazenave coined the term ‘lupus erythemateaux’ (Holubar and 
Fatovic-Ferencic, 2001, Smith and Cyr, 1988) and Wilson later noted that 
the non-ulcerating skin lesion called ‘lupus’ was commoner in women. 
Kaposi called for a clear segregation between ‘lupus vulgaris’ and ‘lupus 
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erythematosus’ (LE). He described the former as an ulcerating lesion that 
was a manifestation of TB and the latter as a separate condition. After the 
discovery of the tubercle bacillus and the failure to isolate the organism from 
LE lesions, the association with TB waned (Wallace and Hahn, 2002).   
 
In 1895, Osler described a group of patients some of whom had LE and 
visceral disease and had a relapsing and remitting pattern. He called this 
condition ‘erythema exudativum multiforme’(Wallace and Hahn, 2002). In 
1902, Sequira and Balean published a series of patients with discoid and 
systemic LE (Smith and Cyr, 1988).This period, during which the systemic 
nature of the condition was being described, is known as the ‘neoclassical’ 
period of the history of SLE (Hochberg, 1991).  
 
By the fifth decade of the twentieth century several immunological 
phenomena were described. The value of these tests lay in their ability to 
assist in making the diagnosis of SLE when the classic skin lesions were 
absent (Wallace and Hahn, 2002). This heralded the onset of the ‘modern’ 
period in the history of the disease (Hochberg, 1991). These features 
included the discovery of the false positive WR, by Reinhart in 1909, the LE 
cell phenomenon, by Hargraves in 1948, the lupus anticoagulant by Conley 
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and Hartman,in 1952, and antinuclear antibodies (ANA) by Miescher and 
Fauconnet in 1954 (Wallace and Hahn, 2002). 
 
1.2 Classification criteria 
1.2.1 Development of classification criteria 
As researchers probed this disease it was recognized that other conditions 
have overlapping clinical features. Criteria to help classify the disease were 
needed especially to facilitate research. Early criteria were described by 
Siegel and Lee in an attempt to standardize diagnosis (Siegel et al., 1962). 
By 1971 the American College of Rheumatology (ACR) considered 74 
criteria as potentially useful. 14 were selected as diagnostic criteria (Cohen 
and Canoso, 1972). One of the aims of these criteria was to differentiate the 
disease from rheumatoid arthritis. Four criteria were needed to confirm the 
diagnosis. In 1982 a positive ANA test was added to the, then revised, ACR 
criteria, and the total number of criteria was reduced to 11 (Tan et al., 1982). 
Further adjustments were proposed by Hochberg to include antiphospholipid 
antibodies (Hochberg, 1997). The 1997 revised criteria are shown in 
Appendix 1.  
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1.2.2 Use and limitations of  ACR classification criteria 
Levin et al have pointed out some limitations of these criteria if used as a 
diagnostic tool. Only 50% of their patients fulfilled the 1982 criteria at the 
onset of the disease (Levin et al., 1984).  However after 5 and 7 years 
respectively this increased to 78.5% and 83%. All of their patients 
eventually fulfilled the criteria, requiring up to 20 years in some instances. 
Alarcon et al report that the mean time to accrual of four criteria was 
29.4(±52) months from first presentation in their cohort (Alarcon et al., 
2004). Davis and Stein applied criteria to 18 Zimbabwean SLE patients, for 
which they found the sensitivities to be 83% and 94% for the 1971 and 1982 
criteria, respectively (Davis and Stein, 1989). Patients with SLE, especially 
with milder disease and at initial presentation may be undiagnosed if the 
‘diagnostic’ criteria are used to define diagnoses, but may contribute to the 
burden of the disease and may need similar therapy (Levin et al., 1984). 
 
In addition to the ACR classification criteria, numerous instruments have 
been developed to measure disease activity, including the SLE disease 
activity index (SLEDAI), systemic lupus activity measure (SLAM) and 
British Isles lupus assessment group (BILAG) scores.  These instruments are 
important from therapeutic and prognostic perspectives. The ACR Systemic 
Lupus International Co-operative Clinics damage (SLICC) score is used to 
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measure irreversible damage that results from both disease activity and drug 
toxicity (Wallace and Hahn, 2002). 
 
1.3 Epidemiology of disease and clinical features 
1.3.1 Disease incidence and prevalence 
Systemic lupus erythematosus occurs in all populations, with the highest 
prevalence described in African -American women.  As with type I diabetes, 
the prevalence varies along what is termed a tropical gradient, with the 
highest figures in temperate regions and lowest in the tropics (Bae et al., 
1998). The annual incidence of the disease varies between 3.3 and 
8.7/100000 people. (Table 1) 
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Table 1 – Incidence of SLE in selected countries  
Study Country Year No Incidence * 
Gudmundsson (Gudmundsson and 
Steinsson, 1990) 
Iceland 1990 76 3.3 
Nossent (Nossent, 1992) Curacao 1992 94 4.6 
Hopkinson (Hopkinson et al., 1993) United 
Kingdom 
1993 23 3.7 
Uramoto (Uramoto et al., 1999) USA 1992 48 5.56 
Vilar (Vilar and Sato, 2002) Brazil 2002 43 8.7 
* per 100 000 people per year 
 
Several groups have documented an increase in the incidence of the disease 
over the latter part of the twentieth century (Uramoto et al., 1999, 
Gudmundsson and Steinsson, 1990). Similarly the prevalence of the disease 
in different parts of the world varies widely from 12 to 254 per 100 000. The 
differences in prevalence may relate to differences in the study populations 
relating to age, sex, ethnicity and environment or differences in the 
methodology of the studies and the criteria used for diagnosis (Wallace and 
Hahn, 2002).  
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1.3.2 Incidence of the disease in Africans 
There are no published studies on the rates of occurrence of SLE in Africa, 
although several centres have reported their experience with SLE. The 
disease is thought to be less common in tropical Africa because of the high 
prevalence of tropical infectious diseases, particularly malaria. This 
phenomenon may be mediated by the presence of immunosuppressive 
mediators like tumour necrosis factor alpha and nitric oxide in patients with 
chronic infection (Adebajo, 1997, Greenwood, 1968).  It is also likely that 
poor access to health services contributes to under diagnosis in Africa. 
Nevertheless, population surveys together with increasing reporting suggest 
that the disease may not be as uncommon in sub-Saharan Africa as once 
believed (Seedat et al., 1994, Ka et al., 1998b, Houman et al., 2004, 
Adebajo and Davis, 1994). Certainly, patients of ethnic African descent 
living in Western countries appear to be quite commonly afflicted with this 
condition (Bae et al., 1998, Molokhia et al., 2003).  Systemic lupus 
erythematosus has been reported to be commoner in Southern Africa than in 
central and West-Africa (McGill and Oyoo, 2002, Symmons, 1995).  There 
is also some suggestion that Asian populations are more prone to the disease 
than whites (Samanta et al., 1992).  Table 2 shows some of the reports from 
Southern Africa. 
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 Table 2. Selected studies from Southern Africa reporting SLE 
Study Year Place Period No. of patients Comment Ref 
Dessein 1988 Pretoria 12 yrs 30 20 of the cases in 2 years; all black (Dessein et al., 1988) 
 Ansell 1996 Johannesburg 10.5 yrs  30 Critical care requiring  (Ansell et al., 1996) 
Sutej 1989 Johannesburg Cross sectional 92 Prospective study examining photosensitivity (Sutej et al., 1989) 
Jessop 1973 Cape Town 11yrs 130 Only 60% fit 1971 criteria;mostly white and coloured (Jessop and Meyers, 1973) 
Seedat 1977 Durban 6 yrs 30 17 Indian, 13 black (Seedat and Pudifin, 1977) 
Stein 1990 Harare 6 mts 18 Prevalent patients seen at clinic (Stein and Davis, 1990) 
Tikly  1996 Soweto Cross sectional 111 Survey of autoantibodies (Tikly et al., 1996) 
Mody 1994 Durban 6 yrs 85 Hospitalised  (Mody et al., 1994) 
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1.3.3 The role of gender and age 
Female sex has consistently been associated with the disease, with a female 
predominance approaching 90% (Wallace and Hahn, 2002). Outside the 
childbearing years the incidence of SLE in males approaches the rate in 
females although it remains higher in females. These differences are thought 
to relate to hormonal influences (Mayor and Vila, 2003). The median age of 
disease onset is between 37 and 50 years in white women (Wallace and 
Hahn, 2002).  Several comparative studies have, however, shown that the 
peak age of onset is lower in black women (Hochberg, 1985, Hopkinson et 
al., 1994). The disease has been reported to occur later in affected males 
(Pistiner et al., 1991, Wallace and Hahn, 2002). 
 
1.3.4 Genetic factors related to disease. 
Familial clustering of patients with SLE has been noted. Hochberg in a case 
control analysis reported that 10% of patients with SLE have at least one 
first degree relative with the disease compared to 1% of age, gender and race 
matched controls (Hochberg, 1987a). A concordance rate between 
monozygotic twins that is about ten times the concordance rate between 
dizygotic twins or non-twin siblings is evident (Bengtsson et al., 2002, 
Cooper et al., 2002a).  Both major histocompatibility complex (MHC) and 
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non-MHC related genes have been linked to SLE susceptibility (Wallace and 
Hahn, 2002). An extensive review of the genes associated with SLE is 
beyond the scope of this report but some of the most consistent are listed 
below.  
• HLA DR2 in Caucasians, Asians and Africans (Wallace and Hahn, 
2002, Rudwaleit et al., 1995). HLA DR3 in many Caucasian  
populations and in some studies in Africans (Reveille et al., 1998, 
Wallace and Hahn, 2002). 
• HLA DR2 and DR3 have been associated with the presence of Anti-
Ro (SSA) and Anti-La (SSB) antibodies (Arnett et al., 1989). 
• Antiphospholipid antibodies were associated with HLA DR7, DR4 
and DRw53 (Wallace and Hahn, 2002). 
• Deficiencies in complement components 2 (C2) and 4 (C4) have both 
been associated with SLE in different populations (Arnett et al., 1990, 
Ayed et al., 2004). 
• Tumour Necrosis Factor (TNF) gene polymorphisms have been 
associated with SLE but may be due to gene linkage (Bettinotti et al., 
1993, Rudwaleit et al., 1996). 
• Several non-MHC encoded loci have been associated with SLE. They 
have in common the fact that they involve genes coding for 
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participants in the immune system and include C1q genes, T-cell 
receptor genes, Fc receptor genes, cytokine genes and TNF receptor 
genes (Wallace and Hahn, 2002). 
• Researchers from Africa have demonstrated several genes associated 
with SLE. Kachru et al in 1984 described associations with HLA DR2 
and DR3 in African patients (Kachru et al., 1984). Klemp et al 
demonstrated that HLA DR2 was associated with a higher risk of SLE 
in Cape Coloured patients (Klemp et al., 1988). Rudwaleit et al in a 
group of 49 patients from our clinic also demonstrated the association 
with DR2 in black patients (Rudwaleit et al., 1995). Davies et al 
showed an association between SLE and mannose-binding protein 
gene polymorphisms in patients from South Africa (Davies et al., 
1998).  
 
1.3.5.Environmental aspects implicated in disease causation 
Despite the above strong evidence for genetic factors that predispose to SLE, 
there exists also strong evidence that environmental factors are partly 
responsible for the development of the disease. An example of 
environmental influence is the observation that in Africa (especially West 
Africa) the disease is uncommon while in people of African extraction living 
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in the developed world the incidence is very high (Molokhia et al., 2001). 
Several environmental factors have been commonly linked with autoimmune 
disease. These include: 
• Chemical factors including aromatic amines and hydrazines- these are 
metabolized by acetylation and ‘slow acetylators’ are at particular 
risk. Exposure to heavy metals including gold and mercury are also 
implicated(Cooper et al., 2004a, Cooper et al., 2004b) 
• Exposure to sunlight especially the UV fraction.(Nived et al., 1993) 
• Infectious agents including Herpes group viruses, and bacterial 
elements have been indirectly linked to autoimmune disease. (Wallace 
and Hahn, 2002, Cooper et al., 2002a). 
 
1.3.6 Differences in clinical features and clinicoserologic correlations 
 
The manifestations of SLE differ significantly among individuals. Several 
epidemiological studies have been performed to look at clinical features and 
their distribution in different populations around the world. The following 
are a few examples. Various studies have revealed a clustering of clinical 
and serological features in particular populations. 
• Naiker et al have demonstrated a prevalence of 45% for 
anticardiolipin antibodies in a population of South African 
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patients with lupus nephritis (Naiker et al., 2000). This 
association has also been described by others along with 
associations of Lupus nephritis with anti-dsDNA antibodies and 
anti-Sm antibodies (Alba et al., 2003). 
• Comparison of patients with and without renal involvement in a 
study from Tunisia showed that lupus nephritis was significantly 
associated with pericarditis, hypertension, cryoglobulinemia and 
antiphospholipid syndrome (Houman et al., 2004).  
• Ribosomal–P autoantibodies have been associated with 
neurological lupus but this has not been a consistent finding 
(Arnett et al., 1996, Gerli et al., 2002). 
• Font et al, in their group of 600 Spanish patients with SLE, 
described numerous correlations including associations between 
renal disease, haemolytic anaemia and anti-dsDNA antibodies 
(Font et al., 2004). 
• Tikly et al also found positive clinicoserological associations 
which included the combination of anti-dsDNA antibodies and 
low complement factor 4 (C4) levels with renal disease; anti-
dsDNA antibodies with cutaneous vasculitis; anti-Sm antibodies 
with psychosis; anti-RNP antibodies with Raynaud's phenomenon 
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and anti-Ro antibodies with renal disease, psychosis and malar 
rash (Tikly et al., 1996).  
 
Furthermore racial and ethnic groups may differ in the pattern of 
manifestations associated with SLE. Cooper et al analyzed racial differences 
in the Southeastern USA and found more discoid lupus, more nephritis and a 
higher prevalence of anti-Sm and anti-RNP antibodies in black patients as 
well as less photosensitivity or mucosal ulcers in black patients (Cooper et 
al., 2002b). A similar finding as regards photosensitivity was reported in 
South African Blacks by Jacyk et al (Jacyk and Steenkamp, 1996). Several 
other investigators have noted the increased incidence of renal disease in 
black patients (Bastian et al., 2002, Hochberg et al., 1985).Gender 
differences have also been described. These include an older age of onset in 
males as well as a greater tendency to renal failure and a higher prevalence 
of serositis. (Mayor and Vila, 2003). 
 
The commonest clinical manifestations reported are articular and cutaneous 
disease. Haematological and renal involvements are also common. The table 
below summarizes the prevalence of these manifestations in studies from the 
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developing world (Dessein et al., 1988, Jessop and Meyers, 1973, Seedat 
and Pudifin, 1977, Houman et al., 2004, Vila et al., 1999). 
 
 
Table 3: Clinical manifestations in selected studies 
Study Jessop 
(Cape 
Town) 
Dessein 
(Pretoria) 
Seedat 
(Durban)
Houman 
(Tunisia) 
Vila 
(Peurto 
Rico) 
Year 1973 1988 1976 2004 1999 
Number 130 30 30 100 134 
Articular 74% 90% 97% 78% 67.5% 
Skin 78% 60% 73% >63% 76.9% 
Renal 58.5% 60% 87% 43% 16.2% 
Haematological 
1.Haemolytic anaemia 
2.Leukopaenia 
3.Thrombocytopaenia 
 
14.5% 
22.3% 
17.7% 
 
 
63% 
10% 
 
 
12% 
3% 
  
12.7% 
41.8% 
ANA (or positive LE)* 90.8%*   100%* 100% 93.3% 
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1.3.7 Incidence of lupus nephritis (LN) and different classes of LN 
The frequency of renal involvement varies in different populations studied 
with both ethnic and geographic variation reported. In a recent study done in 
Tunisia, 43% of patients were diagnosed with lupus nephritis (LN) (Houman 
et al., 2004), while LN was found to be uncommon in an ethnically similar 
Arab population in Israel (Habib and Saliba, 2002). Various studies have 
demonstrated a higher incidence of LN in black patients (Bastian et al., 
2002, Alba et al., 2003). In a study done at Queens medical center in 
Nottingham (UK) by Hopkinson and colleagues only 22% of patients had 
LN (Hopkinson et al., 1993).The histological patterns of lupus nephritis as 
defined by the WHO are shown as appendix 2 in simplified form. The table 
below demonstrates the prevalence of the different subtypes in several 
studies (Seedat et al., 1994, Mok et al., 1999, Bates et al., 1991, Bastian et 
al., 2002, Neumann et al., 1995). 
Table 4: WHO subtype in selected studies 
WHO subtype  N I II III IV V VI 
Bates et al(1991) S Africa 55 - 11% 24% 58% 7% - 
Seedat et al(1994)$ S Africa 43 5% 35% 7% 40% 9% - 
Neumann et al(1995)# USA 150 0.6% 7% 13% 46% 11% 5% 
Mok et al(1999) S China 183 1% 5% 25% 55% 14% - 
Bastian et al(2002)* USA 43 - 21% 33% 35% 41% - 
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$ 1 biopsy showed interstitial nephritis; #  10% classification not determinable; * In this 
study where two classes of LN were reported both were counted.  
 
1.4 Mortality data 
1.4.1. Trends in Mortality 
 
In the preceding five decades significant advances have been made in the 
management of SLE. Initial strides in improving diagnosis, especially with 
serology, allowed appropriate treatment. The prognosis of SLE has 
improved with the widespread use of corticosteroids. The advent of other 
immune suppressants in the last few decades has conversely allowed us to 
diminish the overall exposure to steroids while maintaining efficacy of 
immunosuppression to further improve outcomes. Better supportive care in 
the form of ICU services, dialysis, transplantation and antibiotics have 
contributed to improving survival (Wallace and Hahn, 2002).  
 
An observational study done in 1956 by Dubois’ group, which included 
patients from the pre-steroid era, demonstrated a five year survival of only 
40%, a study by Ginzler et al showed a 77% 5 year survival in 1982 while 
more recent studies have demonstrated 5 year survival figures exceeding 
90% in developed countries (Dubois, 1956, Ginzler et al., 1982, Cervera et 
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al., 1999). Studies in the developing world, from India, Curacao, Tunisia and 
Thailand have shown that survival has not been as good in these countries 
(Malaviya et al., 1997, Nossent, 1993b, Kasitanon et al., 2002). In South 
Africa Jessop et al described a 5 year survival rate of 65.5% in 130 patients 
in Cape Town in 1973 (Jessop and Meyers, 1973).  Dessein et al, in 30 
patients from Pretoria, reported their five year mortality as 78% (Dessein et 
al., 1988). A study from Durban also revealed a high mortality rate in 
hospitalized patients with SLE (Mody et al., 1994). Similarly Ansell et al 
showed a high mortality in a group of critically ill patients with SLE in 
Johannesburg (Ansell et al., 1996) as did Whitelaw in Cape Town 
(Whitelaw et al., 2005). Even in more developed nations however, patients 
with SLE are still more likely to die than those without the disease (Urowitz 
et al., 1997).  
 
1.4.2 Causes of death 
Before the advent of corticosteroids and immunosuppressants, disease 
activity was the commonest cause of death with most deaths occurring soon 
after diagnosis (Wallace et al., 1982, Dubois et al., 1978).  More recently, 
mortality in the developed world seems to follow an established, disease 
duration related pattern. Early deaths (within 5 years) are more often due to 
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disease activity or infections. Deaths after this are more likely to be due to 
malignancy or vascular disease (Cervera et al., 2003, Moss et al., 2002). The 
increased incidence of cardiovascular disease is not fully explained by 
traditional risk factors alone (Gorman and Isenberg, 2004).  
 
Several studies from the developing world, although mostly consisting of 
small numbers of patients, have demonstrated that infection and active 
disease, particularly with renal involvement or renal failure, are the major 
causes of death and that the early mortality (within five years) is higher than 
that in the developed world (Kasitanon et al., 2002, Houman et al., 2004, 
Seedat et al., 1994). Table 5 demonstrates the causes of death as reported in 
various selected studies from around the world (Moss et al., 2002, Seedat 
and Pudifin, 1977, Abu-Shakra et al., 1995a, Jacobsen et al., 1998, Ka et al., 
1998a, Cervera et al., 2003)
 20
 
 
Table 5: Causes of death in SLE –selected studies 
Study Country Year  Number Deaths Infections Renal Cardiovascular Malignancy Activity unknown Other 
Seedat S.Africa 1977 30 6 - 33% 15% - - 33% - 
Abu 
Shakra 
Canada 1995 665 124 40% 4.8% 15.4% 6.5% 16% 10.5% 14.6%
Jacobsen Denmark 1998 513 122 20.4%  26.2% 7.3% 28.6%  17.2%
Ka Senegal 1998 30 8 25% 37.5% - - - - 37.5%
Moss UK 2002 300 41 17% 15% 17% 20% - 10% 22% 
Cervera Spain 2003 1000 68 25%    26.5%  26.5%
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1.4.3. Predictors of mortality 
Several investigators have attempted to define features that predict a poor 
outcome. Conflicting data regarding the effect of age at diagnosis have been 
reported. Kaslow commented on the effects of increasing age on mortality 
(Kaslow and Masi, 1978). More recently Abu Shakra also reported that 
increasing age was independently associated with mortality (Abu-Shakra et 
al., 1995b). However older age has not been consistently found to be a 
predictor of mortality in all studies. Gender differences in mortality are also 
inconsistent but some studies have noted a poorer prognosis in males 
(Molina et al., 1996, Mayor and Vila, 2003). Others have found no effect on 
mortality of male sex (Hochberg, 1987b).  Black race has been shown to be 
associated with poorer outcome as has non-white race in other series (Walsh 
et al., 1996, Ward et al., 1995). This is confounded by the finding that lower 
socioeconomic status has also been associated with poorer outcome in some 
of these studies.(Alarcon et al., 2001, Lotstein et al., 1998) 
 
Several studies have demonstrated renal disease to be a poor prognostic 
feature (Abu-Shakra et al., 1995b, Bellomio et al., 2000).In addition patients 
with more advanced renal disease as evidenced by more severe 
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hypertension, higher degrees of proteinuria, proliferative disease or fibrosis 
on biopsy and renal dysfunction have the worst prognosis (Donadio et al., 
1995, Mok et al., 1999). Black patients may also have a poorer outcome of 
nephritis (Dooley et al., 1997, Nossent, 1993a). Thrombocytopenia, lung 
involvement, neurological involvement, cardiac disease, antiphospholipid 
antibodies, SLE disease activity index (SLEDAI) score and high damage 
scores are other factors which have been reported to be predictors of poor 
outcome in several studies (Wallace and Hahn, 2002). 
 
1.5 Aims and Objectives 
In view of paucity of data on causes and predictors of death in Africans, we 
undertook a retrospective study of Black South African patients attending 
the Lupus clinic at Chris Hani Baragwanath Hospital (CHBH), the major 
tertiary referral facility that serves the people of Soweto and surrounding 
areas of southern Gauteng. 
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2. Patients and Methods 
2.1 Description of study and inclusion criteria 
A retrospective review of available clinical records of patients fulfilling the 
1997 ACR criteria for SLE or features of SLE-like disease (3 criteria) and 
attending the Lupus clinic at CHBH was performed. Only records of patients 
who were admitted or who were seen on more than one occasion were 
included in the analysis. 
 
2.2 Clinical and laboratory data abstraction 
Demographic, clinical and serological data was abstracted from the clinic 
records. The clinical and laboratory features present, which corresponded to 
the ACR classification criteria for SLE, were recorded if clearly noted in the 
records. Clinical features were further stratified according to whether they 
were present at diagnosis (or within one month of presentation) or whether 
they developed subsequently. Laboratory features were however only 
recorded as being present or absent at any time. 
 
Serological tests that were documented included the anti-nuclear antibody 
(ANA) test, antibodies to the extractable nuclear antigens RNP, SM, Ro and 
La, anti double stranded-DNA antibodies and anti-phospholipid antibodies 
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(either a positive IgG or IgM anticardiolipin antibody test or a positive test 
for lupus anticoagulant).  The presence of hypocomplementaemia (low C3 or 
C4) was also recorded. Appendix 3 is an example of the form used to record 
data. 
 
2.3 Recording outcomes 
Outcomes were recorded as known or unknown. Known outcomes were 
further stratified as known alive or known dead. Causes of death were 
determined from the available records in patients known to have died. The 
causes were classified as follows:  
• Infections (sepsis) – where the cause of death was found to be 
definitively caused by an infective aetiology or by a syndrome 
characteristic of infection (e.g. pneumonia with raised white cells and 
C-reactive protein). 
• Renal failure -where patients had markedly deranged creatinine and 
were thought to have died as a result of renal metabolic complications. 
• Active disease - where death occurred directly as a result of a serious 
manifestation of SLE but not renal failure.  
• Other - where death was not directly attributable to SLE but was 
caused by any other condition (e.g. cardiovascular disease). 
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The causes of deaths were assigned into one of the above categories by 
careful review of the records by Dr S Wadee and Professor M Tikly. Where 
no cause of death was recorded in the file this was classified as unknown. 
Indirect contributors to mortality were assessed based on a subjective 
assessment of the records at the time of death. 
 
2.4 Statistical Methods 
The Chi-square test and Student’s t- test or ANOVA analysis were applied 
to compare nominal and continuous variables, respectively, between patient 
subgroups. Kaplan-Meier survival curves were constructed to assess the 
overall survival figures and for subgroups of patients. A multivariate logistic 
regression analysis of the variables that were associated with mortality was 
performed using the Cox proportional hazard model.  Statistical analyses 
were performed using Statistica v6 (Statistica.com). A p value < 0.05 was 
defined as being statistically significant.  
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3.0 Results 
3.1 Overview of files reviewed 
Of 280 patients reviewed, 10 were excluded either because records were 
inadequate (3), the diagnosis was not SLE (2) or records were not traceable 
at the time of the analysis (5). Of the remaining 270 patients, 226 patients 
fulfilled at least 4 ACR classification criteria for a diagnosis of SLE while 
44 patients met 3 criteria and were defined as ‘SLE like’. The records dated 
from January 1986 to July 2003. Figure 1 below shows the breakdown of the 
records reviewed. The demographic description of the population studied is 
summarized in table 6 below
 27
. 
Still at clinic
n=107
(47.3%)
Died
n=55
(15.5%)
Lost to follow up
n=64
(28.2%)
Fulfilled criteria for SLE
n=226
Still at clinic
n=17
(38.7%)
Died
n=5
(11.4%)
Lost to follow up
n=22
(50%)
< 4 ACR criteria for SLE
n=44
Inadequate information
n=10
Total no of records reviewed
n=280
 
 
Figure 1 –Overview of records reviewed
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3.2 Demographic analysis 
The demographic and outcome data are summarized in table 6. The mean 
age at presentation was 34 years. The mean age at presentation in males with 
SLE (38.9yrs) was not significantly different from that in females (33.7 yrs). 
Differences between the SLE group and SLE like group are also shown. The 
mean follow up was significantly shorter (p<0.0001) in the SLE-like group. 
Half of the SLE-like patients were lost to follow up. A significantly higher 
proportion of the patients classified as SLE-like were lost to follow up ( Chi 
Squared -p<0.01). 
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TABLE 6: Demographic data  
 SLE (no=226) SLE-like (no=44) Overall (n=270) 
Male: Female  1:18 1:15 1:16 
Mean(±SD) age (years)  34(±12.5)  35.9(±13.4)  34.3(±12.7)  
Mean(±SD) follow up(months) 59.4(±49)* 27.3(±31.3) 54.2(±48) 
Known deaths 55(24.3%) 5(11.4%) 60(22.2%) 
Lost to follow up 64(28.3%)$ 22(50%) 86(31.9%) 
*p<0.0001 versus SLE like group;   $p<0.01 versus SLE like group 
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3.3 Prevalence of clinical features and differences between groups based 
on outcome. 
 
The clinical features found at presentation are displayed in table 7 and the 
cumulative incidences of various ACR clinical and serological criteria are 
shown in Table 8 below. The demographic and clinical features of the 
subgroups of known alive, known dead and patients lost to follow up at the 
time of analysis, are summarized in table 8.   
 
TABLE 7 - Frequencies of clinical features found at initial presentation in 226 
patients with SLE 
Clinical Feature Frequency 
Malar rash 105 (46.5%) 
Discoid rash 79 (35%) 
Photosensitivity 80 (35.4%) 
Oral ulcers 50 (22.1%) 
Arthritis 115 (50.9%) 
Nephritis 77 (34.1%) 
Neurological disease 20 (8.8%) 
Serositis 38 (16.8%) 
 
 31
Table 8 Cumulative frequency of clinical and laboratory findings in 226 patients fulfilling ACR criteria 
for SLE 
ACR criteria/feature Total (226) Dead (55) Known alive 
(107) 
Lost to follow up 
(64) 
p-value1 
Mean age ±SD (yrs) 33.9 ±12.5 34 ±14.3 33.7 ±11.1 34.4 ±13.3 NS 
Mean follow up ±SD (mts) 59.4 ±49 46.7 ±43.3 82.2 ±46.3 32.3 ±39.5 0.00012 
Malar rash 132 (58.4%) 34 (61.8%) 60 (56.1%) 38 (59.3%) NS 
Discoid lupus 94 (41.5%) 19 (34.5%) 47 (43.9%) 28 (43.8%) NS 
Oral ulcers 87 (38.5%) 28 (50.9%) 39 (36.4%) 20 (31.3%) NS3 
Photosensitivity 88 (38.9%) 20 (36.3%) 37 (34.6%) 31 (48.4%) NS 
Serositis 41 (18.1%) 12 (21.8%) 16 (14.9%) 13 (20.3%) NS 
Arthritis 159 (70.4%) 35 (63.6%) 83 (77.5%) 41 (64.1%) NS 
Neurological disease 36 (15.9%) 14 (25.4%) 12 (11.2%) 10 (15.6%) NS4  
Nephritis 99 (43.8%) 35 (63.6%) 39 (36.4%) 25 (39.1%) 0.01 
Haematological disease 
   Thrombocytopaenia 
118 (52.2%) 
   29(12.8%) 
21 (38.2%) 
   6(10.9%) 
65 (60.7%) 
   12(11.2%) 
32 (50%) 
   11(17.2%) 
0.025 
NS 
ANA positive 224 (99.1%) 55 (100%) 105 (98.1%) 64 (100%) NS 
Any other immunological 
criteria(dsDNA,Sm orAPL) 
179 (79.2%) 45 (81.8%) 83 (77.5%) 51 (79.6%) NS 
Anti-dsDNA antibodies 125 (55.3%) 33 (60%) 61 (57%) 31 (48.4%) NS 
Anti-Sm antibodies 92 (40.7%) 23 (41.8%) 41 (38.3%) 28 (43.8%) NS 
Antiphospholipid antibodies 61 (27%) 16 (29.1%) 32 (29.9%) 13 (20.3%) NS 
Hypocomplementaemia 147 (65%) 44 (80%) 67 (62.6%) 36 (56.3%) 0.025 
1.All p values above reflect results when analysis includes all 3 groups. 
2. Known alive vs Lost to follow up and Known alive Vs Known Dead. (1-way ANOVA) 
3. Not significant overall but p< 0.05 if dead compared to (known + unknown) together (Chi-squared) 
4. Not significant overall but p< 0.05 if dead compared to (known + unknown) together (Chi-squared) 
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Arthritis was the commonest presenting clinical feature. Cutaneous 
manifestations of SLE were also common presenting clinical features. While 
78% of patients with nephritis had it at presentation only 56% of patients 
with CNS lupus presented with it. As shown in table 8 nephritis, 
neurological disease and hypocomplementaemia were significantly more 
common in patients who were known to have died compared to the known 
alive and lost to follow up group. Mean follow up was significantly longer in 
the known alive group (1-way ANOVA p<0.0001).  On multivariate analysis 
using the Cox proportional hazard regression model for all the factors in 
table 8 only nephritis was independently associated with death. The relative 
risk of death in patients with renal disease was 2.07 (95% confidence 
interval  = 1.11-3.84) p<0.0007. 
 
Table 9 below shows the cumulative clinical and serological features in the 
SLE-like group. The difference in follow up of the patients known to be 
alive was statistically significantly longer than that for the other groups 
(p<0.004 ). None of the other differences between the three subgroups in the 
table were statistically significant. 
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Table 9 Cumulative frequency of clinical and laboratory findings in 44 patients not fulfilling ACR 
criteria for SLE (SLE-Like) 
ACR criteria/feature Total (44) Dead (5) Known alive 
(17) 
Lost to follow up 
(22) 
p- value 
Mean Age ± SD years 35.9±13.4 32.2±8.7 36.8± 10.7 36±16.2 NS 
Mean Follow up ±SD mts 27.3±31.3 11.4±9.9 46.9±35.4 15.8±22.8 <0.004 
Malar rash 3 (6.8%) 0 0 3 (13.6%) NS 
Discoid lupus 7 (15.9%) 2 (40%) 1 (5.9%) 4 (18.2%) NS 
Oral ulcers 2 (4.5%) 0 1 (5.9%) 1 (4.5%) NS 
Photosensitivity 4 (9%) 0 1 (5.9%) 3 (13.6%) NS 
Serositis 2 (4.5%) 0 1 (5.9%) 1 (4.5%) NS 
Arthritis 26 (59.1%) 3 (60%) 13 (76.5%) 10 (45.4%) NS 
Neurological 1 (2.3%) 1 (20%) 0 0 NS 
Renal 9 (20.5%) 1 (20%) 2 (11.8%) 6 (27.2%) NS 
Haematological 7 (15.9%) 1 (20%) 4 (23.5%) 2 (9.1%) NS 
ANA positive 41 (93.2%) 5 (100%) 15 (88.2%) 21 (95.5%) NS 
 Immunological 
criteria(dsDNA,Sm,APL) 
18 (41%) 1 (20%) 7 (41.2%) 10 (45.4%) NS 
Hypocomplementaemia 16 (36.3%) 2 (40%) 9 (52.9%) 5 (22.7%) NS 
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3.4 Causes of death 
A total of 55 patients (24.3%) with SLE were known to have died. The mean 
(±SD) age at the time of death was 37.8 (±13.9) years. Table 10 below 
demonstrates the causes of death as classified. The cause of death was 
known in 40 patients. The largest proportion of patients (32.7%) died as a 
result of infections. Infections ranged from Tuberculosis and pneumonia to 
staphylococcal septicaemia. The details of the causes of infective deaths are 
shown in Table 11. There were no known viral causes of infective deaths 
however two patients who succumbed to sepsis also had associated HIV 
infection. Renal failure in 16.4% of patients was the second commonest 
known cause of death. Of seven deaths in the ‘other’ group only one was 
from a presumed atherosclerotic cause - a myocardial infarct, three were 
from cardiomyopathies, two were from pulmonary vascular diseases and one 
was pregnancy related. The relative causes of death within 5 years of 
presentation and thereafter are also shown in Table 10. No death due to 
malignancy was recorded. Active lupus and renal disease were the main 
indirect contributors to death where they were not themselves the cause of 
death. In the group of lupus-like patients 5 deaths occurred. Three were due 
to infection, one due to renal failure and in one the cause was unknown. 
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Notes-table 10.  
1. Myocardial infarct at 43 years of age after 53 months of follow up in patient with positive anti-
phospholipid antibodies and previous stroke. 
2. One pulmonary embolus after 3 months of follow up and one patient with chronic progressive 
pulmonary hypertension 
3. Complications resulting from foetal loss in a patient with recurrent foetal losses  
 
 
 
Table 10 - Causes of death in patients with SLE 
Causes of death 
 
<5years  >5 Years Total 
Infection 13 5 18 (32.7%) 
Renal 6 3 9 (16.4%) 
Active disease 4 2 6 (10.9%) 
Other  5 2 7 (12.7%) 
  Acute cardiovascular1     1     0  
  Pulmonary circulatory2     1     1  
  Pregnancy related3     1     0  
  Cardiomyopathies     2     1  
Unknown 12 3 15 (27.3%) 
Total 40 (72.7%) 15 (27.3%) 55 
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Table 11- Details of infective causes of death 
Type of infection <5 years >5years Total 
Sepsis/Septicaemia 
unspecified 
4 2 6 
Pneumonia unspecified 4 1 5 
Tuberculosis1 1 2 3 
PCP pneumonia 1  1 
Meningitis 1  1 
Post surgical sepsis 1  1 
Pyomyositis 1  1 
Total2 13 5 18 
 
 
Notes –Table 11 
1. Two of the three patients had drug resistant TB. TB also contributed to death in one other patient 
whose primary cause of death was due to a cardiomyopathy. 
2. HIV infection was a possible co-factor in two infective deaths, one with TB and one with 
Pneumonia. 
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Figure 2: Indirect contributors to 
mortality
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Figure 2 above shows the indirect contributors to mortality in the opinion of 
the reviewers. These were factors which were present in patients who died in 
addition to the assigned cause of death. 
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3.5 Survival curves 
The Kaplan Meier survival curves for patients with SLE demonstrate an 
overall 5-year survival rate of 57% (figure 3). Five-year survival if censored 
for those lost to follow up is 72% (figure 4). Figure 5 indicates the 
magnitude of the survival difference between those with or without renal 
disease censored for patients lost to follow up. It is stratified as to whether 
disease was present at initial presentation, developed during follow up, or 
was never noted. It can be seen that the survival is worst for those that 
develop the disease early but that renal disease at any time is a poor 
prognostic indicator. These differences were statistically significant 
(p=0.002). CNS disease and hypocomplementaemia were also associated 
with poorer survival. (p=0.007 and p=0.031 respectively). 
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Figure 3- Survival of patients at clinic 
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Figure 4- Patient survival excluding lost to follow up group 
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Chi² = 12.4338 df = 3 p = 0.002
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Figure 5- Survival with and without nephritis (lost to follow up 
group excluded) 
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Cox's F-Test (Raw data.sta)
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Figure 6- Survival with and without CNS disease (lost to follow 
up group excluded) 
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Figure 7- Survival with and without hypocomplementaemia 
disease (lost to follow up group excluded) 
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4.Discussion 
This review of patients from Soweto in Gauteng Province, South Africa 
consists of an analysis of 270 patients for whom records were available. The 
analysis spans a period of more than sixteen years. This analysis constitutes 
the largest single group of patients reported in South Africa. Two hundred 
and twenty six of these patients fulfilled the ACR criteria for SLE out of the 
270 files examined.  
 
4.1 Demographic features and classification by outcome. 
 
The age at presentation of the patients diagnosed with SLE is well within the 
range reported elsewhere. The disease overwhelmingly is one affecting 
young females, usually in their thirties. Only 12 of 226 patients were male 
(5.3%). This exceeds the degree of female predominance in most reports 
(Wallace and Hahn, 2002). The reason for this is not clear but may reflect 
variation in the female predominance in our population. It is possible that the 
well-known female preponderance in this condition leads to missed 
diagnosis in some males with the disease.  The mean age of presentation was 
similar in males and females. On closer analysis however it can be noted that 
the ages of presentation in the males were skewed towards the very young 
and the old. Only 3 of the 12 males presented between the ages of 20-40 
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years compared to the almost 60% of females who presented in this age 
group. This would be partly in keeping with other studies that have 
demonstrated an older age of onset for males.  The average follow up at just 
over five years reflects the fact that this is an established clinic with the 
longest follow up of a patient being for a period of over 16 years. This 
review is unable to provide any estimate of the true prevalence or incidence 
of the disease in our population. This is due to several reasons. The 
population in Soweto has been in major flux over the past few decades and 
has been further impacted on by the arrival in South Africa of several 
immigrant groups from neighboring countries. It is also likely that several 
patients with SLE from Soweto presented to and received treatment at other 
hospitals in the public or private sectors. Further, estimates of occurrence of 
the disease are complicated by the fact that many of our patients are known 
to be from other areas within the broader referral base of the Chris Hani 
Baragwanath hospital. 
 
 
4.2 Clinical features 
The most prevalent clinical feature in this group is arthritis. This finding 
does not conflict with findings from elsewhere in South African populations 
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(Dessein et al., 1988, Seedat and Pudifin, 1977). Skin manifestations were 
also common. Photosensitivity was previously reported to be less common 
in black patients and was reported in 38.9% of patients. This is however 
higher than the prevalence of 13% reported by Dessein et al in his cohort of 
30 black patients (Dessein et al., 1988). The presence of this feature is often 
subjectively assessed based on the experience of the patient. Oral ulcers 
were also reported in <40% of patients. It is possible that this clinical feature 
may be missed as these are usually painless ulcers and may not be reported 
by the patient. 
 
Neurological disease is the least common clinical feature found in this group 
(15.9%). This however represents only new onset seizures or psychosis. It is 
likely that the total burden of neurological disease is higher if commoner 
lesions like neuropathies are included. Renal disease occurred commonly but 
was not as common as that (>60%) reported by Seedat et al, Dessein et al or 
Jessop and Meyers from previous South African series (Jessop and Meyers, 
1973, Dessein et al., 1988, Seedat et al., 1994). The prevalence of renal and 
neurological disease is also less than that reported by Mody in a hospitalized 
group of patients. This likely indicates that those requiring hospitalization 
were more likely to have major organ involvement.(Mody et al., 1994) 
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Renal disease, neurological disease and hypocomplementaemia were 
associated with mortality. Renal, and neurological diseases are areas in 
which disease may directly lead to death via major dysfunction of these 
organs. It is likely that hypocomplementaemia represents a surrogate for 
disease activity.  Haematological disease, which in various previous reviews 
has been associated with mortality, was in fact statistically significantly 
commoner in patients known to be still alive. Thrombocytopaenia 
specifically, which has particularly been a poor prognostic factor in some 
studies was also less common in patients who died. 
 
 4.3 Causes of Death 
Infection was the commonest cause of death. Contrary to findings in 
industrialized nations this remained so even for deaths after 5 years (late 
deaths). This is similar to the findings elsewhere in the developing world 
(Kumar et al., 1992, Malaviya et al., 1997, Kasitanon et al., 2002). The 
predisposition to infection is a well documented feature of SLE (Gladman et 
al., 2002). This may be attributed to both disease and treatment related 
features. In the developed world early deaths are also mostly due to infection 
and reflect the active nature of the disease early on and the high exposures to 
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immunosuppressant medication. The patients in these populations who 
survive beyond 5 years have been selected out and have a separate set of 
morbidities to deal with. They are more likely to have accrued a cumulative 
amount of damage from SLE as well as from exposure to 
immunosuppression, which may manifest (at least in the industrialized 
world) as malignancy and cardiovascular disease (Moss et al., 2002, Abu-
Shakra et al., 1995a). 
 
In our setting the high background prevalence of tuberculosis and HIV 
disease make these constant threats. Only two of the deaths had co-existent 
HIV at the time of death. However HIV disease increases the incidence of 
TB, respiratory illnesses, gastroenteritis and other communicable diseases. 
 
Renal disease was also a common cause of mortality and reflects the 
somewhat limited availability of dialysis. This is similar to the findings from 
elsewhere in Africa (Ka et al., 1998a). One of the problems is that the co-
morbidities in these patients may make dialysis difficult. Another problem in 
our setting contributing to increased mortality from infection as well as from 
renal disease is the somewhat limited availability of appropriate intensive 
care facilities. Even if patients are admitted to an ICU Ansell et al and 
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recently Whitelaw et al have demonstrated a high mortality in these patients 
in South African settings(Ansell et al., 1996, Whitelaw et al., 2005). The 
Chris Hani Baragwanath hospital was until the end of the apartheid 
dispensation deliberately under-resourced and this is likely a further factor 
contributing to the finding of a poor outcome in these patients. 
 
The background prevalence of ischaemic heart disease is thought to be lower 
in South African black patients. However the rising prevalence of diabetes 
mellitus, smoking and obesity means that this is changing. As disease 
patterns in our population change and if deaths from other causes can be 
prevented more effectively this may be a future challenge for our population 
(Seedat, 1996, Bradshaw et al., 2002, Walker et al., 2004). 
 
Active disease as a direct cause of death was recorded in 5 patients. 
However active disease contributed to death in many more patients 
essentially by predisposing to infection or major organ failure.  
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4.4 Survival curves 
The five-year survival at the clinic is poor and is similar to that in other 
developing nations. It is possible that this is an underestimate of patients 
truly surviving. This is because of the relatively large group of patients lost 
to follow up. 28.3% of our patients were lost to follow up. These patients 
may possibly have moved to another centre, gone to the private sector or 
died. An intriguing possibility is that many of these patients may have had 
mild disease and may be being followed up at local general practitioners or 
clinics. Interestingly the mean follow up of these lost to follow up patients 
was only just over half that of the group that are known to be alive (this 
difference was statistically significant -p<0.0001)). However it was not quite 
statistically different from those who died, although it was shorter. Given 
these observations it is difficult to comment on whether these patients are 
still alive and if they died, when they died. It is notable however that in 
terms of clinical features this group did not have any statistically significant 
differences when compared to the known alive group. It could however be 
argued that given more time (i.e longer follow up) some of these patients 
may have accrued major organ involvement. 
For similar reasons the five-year survival if the lost to follow up group are 
excluded is likely to be an overestimate. Bearing these points in mind then, 
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we can only confidently say that the true five-year survival (both in the 
clinic and/or the community) lies between these two figures. This would still 
mean that at least a quarter of our patients die within five years. This somber 
detail means that the outcome of SLE in our population is as bad as in other 
areas in the developing world (Malaviya et al., 1997). 
 
By ten years the survival at the clinic is less than 40%. In the sense of 
survival from this disease we are still lagging behind the developed world. I 
believe that this reflects partly the overall health of our systems of patient 
care. There is however also the indication from studies worldwide that the 
outcome of the disease is poorer in people of African origin and with poor 
socioeconomic circumstances. The disease may occur earlier, be more active 
and have a higher incidence of major organ (particularly renal involvement) 
(Alarcon et al., 2001, Kaslow and Masi, 1978, Mody et al., 1994). 
 
As indicated in figure 5, survival in patients with renal disease was 
significantly worse than those without renal disease. If this graph is not 
censored for those lost to follow up however, this difference is not 
significant. This is because most of the patients lost to follow up did not 
have renal disease yet they did not ‘survive’ at the clinic. Further it can be 
 52
seen that death occurred as a consequence of the nephritis. In the patients 
who only got nephritis later in their disease the initial survival curve matches 
that of those without renal disease. Later however it ‘catches up with the 
poorer curve of those who had renal disease at initial presentation. 
 
4.5 The SLE-like group 
As discussed earlier the classification criteria are not necessarily for 
diagnostic use and several of the patients who are ‘SLE-like’ may be 
indistinguishable in their clinical course from those defined as SLE (Alarcon 
et al., 2004). The suggestion that these are patients who are evolving into 
definitive SLE may have merit. The mean follow up of these patients was 
only 27.3 months, less than half the follow up of the ‘SLE’ group of 60.4 
months. Only 5 of 44 of these patients had been followed up for more than 
five years. Of all the records reviewed only these 5 of 102 patients (4,9%) 
who were followed up for more than 5 years in our clinic did not fulfill 4 
ACR criteria. In the earlier mentioned work by Levin et al and Alarcon et al, 
some patients (though a very small fraction) required more than 20 years to 
achieve a ‘diagnosis’ of SLE (Levin et al., 1984, Alarcon et al., 2004). 
Furthermore half of our ‘SLE-like’ patients were lost to follow up. Another 
factor influencing their diagnostic status is the quality of record keeping and 
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reporting of features by clinicians in the files of these patients. It certainly is 
possible that clinical features were overlooked or inadequately recorded 
which would have conferred a ‘diagnosis’ of SLE on these patients (for 
better or worse). Even though they did not fulfill clinical criteria for SLE, 5 
of these patients died. The causes of death were also related to infection and 
kidney disease. The prevalence of neurological, renal or haematologic 
features were all lower than in the SLE group. This suggests that these 
patients may have had milder disease overall, at least during the period they 
were followed up. Before they were lost to follow up almost 40% of these 
patients however, had nephritis. It is possible that some of these patients 
may have reached end stage renal failure and may be on renal replacement 
therapy. Some studies have shown that renal failure may attenuate SLE 
disease activity and these patients may therefore have stopped coming to 
lupus clinic (Coplon et al., 1983). 
 
 
The intention of this review however, was to assess clinical and outcome 
measures in patients with ‘diagnosed’ SLE. This allows us to compare this 
population’s features with that of other populations. While the limited results 
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of the lupus-like group allow us to make the point of their contribution to the 
burden of the disease they do not form a major focus of this paper. 
 
 
4.6 Limitations 
Any retrospective review is prone to certain types of error. The most obvious 
is that there is likely to be problems with the data recorded. Missing 
information, inconsistencies in data recording in the records by different 
clinicians and problems with interpretation of data recorded may occur. This 
may particularly affect the descriptive aspects of this study. While this may 
occur in a random fashion certain aspects of the analysis may be 
disproportionately affected. An example is the possibility that certain 
clinical features (like oral ulcers), which may cause less discomfort may be 
under recorded. 
 
This review may also be prone to various types of statistical error. Because 
recorded variables may have a small effect and sample size is not set 
beforehand, Type 2 errors cannot be excluded (i.e. the tests may be under-
powered). 
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Another limitation of this particular review is the fact that treatments were 
not recorded on the database and the impact of the different therapies on 
survival, clinical features and morbidity is not reported. This was done 
because of the difficulty recording the actual therapy that patients received, 
especially as in-patients. The standards of care in terms of the therapy 
available also changed over this period. The difficulty of this task however 
may be overcome and it is possible that with a more intensive search through 
other hospital records future comments could be made on the impact of 
therapy in this group. Patient data recording organ damage and SLEDAI 
scores were also not done routinely and the impact of these factors on 
mortality could not be assessed. 
 
The large number of patients lost to follow up also interferes with our ability 
to interpret the data correctly. The nature of these patients is unclear and 
their actual outcomes unknown. 
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4.7 Conclusions 
Some important conclusions can be drawn from this study despite the above 
limitations.  
1. The demographic distribution of patients with SLE in this study 
resembles that from other areas in the world although with a stronger 
female predominance, especially in the childbearing period. Males 
may have an older age of onset but the numbers were too small to 
draw firm conclusions. 
2. Joint and skin involvement are the commonest manifestations of the 
disease. 
3. Renal involvement is independently associated with poor outcome on 
this analysis. 
4. Infection is the commonest cause of death both in the initial period as 
well as later in the disease course. Renal failure is also a common 
cause of death. 
5. Survival is poor in our patients over this period and is in keeping with 
data from elsewhere in the developing world. Loss to follow up is a 
further serious problem that we face. 
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Systemic lupus erythematosus is certainly not a rare disease in South Africa. 
From the above study it can clearly be appreciated that the disease 
contributes significantly to the poor survival of people who have it.  
 
Further research in this area that is needed includes: 
1. Population-based studies to adequately assess the incidence of this 
disease and the amount of a burden it places on our society. 
2. Prospective studies to assess the influence of various features on 
outcome as well as the impacts of therapy on the disease. 
3. Basic science investigations to answer the questions of how to 
identify patients at risk for this condition using genetic and other 
markers. 
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APPENDICES 
Appendix 1 
The 1997 revised ACR criteria for the diagnosis of SLE 
Criterion Description 
1.Malar rash Fixed malar erythema, flat or raised 
2.Discoid rash Erythematous-raised patches with keratotic scaling and follicular 
plugging; atrophic scarring may occur in older lesions 
3.Photosensitivity Skin rash as an unusual reaction to sunlight, by patient history or 
physician observation 
4.Oral ulcers Oral or nasopharyngeal ulcers, usually painless, observed by 
physician 
5.Arthritis Non erosive arthritis involving two or more peripheral joints, 
characterized by tenderness swelling or effusion 
6.Serositis a. Pleuritis (convincing history of pleuritic pain or rub heard 
by physician or evidence of pleural effusion) or 
b. Pericarditis (documented by ECG , rub, or evidence of 
pericardial effusion) 
7.Renal disorder a. Persistent proteinuria (>0,5g/d or 3+) 
b. Cellular casts of any type 
8.Neurologic 
disorder 
a. Seizures (in the absence of other causes) or 
b. Psychosis (in the absence of other causes) 
9.Haematologic a. Haemolytic anaemia or 
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disorder b. Leukopaenia (<4000/mm3 on two or more occasions) or 
c. Lymphopaenia (<1500/mm3 on two or more occasions or 
d. Thrombocytopaenia (<100 000/mm3 in the absence of 
offending drugs) 
10.Immunologic 
disorder 
a. Anti double stranded DNA or 
b. Anti –Sm or 
c. Positive finding of antiphospholipid antibodies based on (1) 
abnormal serum level of  IgG or IgM anticardiolipin 
antibodies, (2) a positive test for lupus anticoagulant ,or 
(3) a false positive serologic test for syphilis known to be 
positive for at least 6 months and confirmed by 
Treponema pallidum immobilization or fluorescent 
treponemal antibody absorption test 
11.Antinuclear 
antibody (ANA) 
Abnormal titre of ANA by immunofluorescence or equivalent 
assay at any time and in the absence of drugs known to be 
associated  
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Appendix 2 
WHO classification of Lupus nephritis 
WHO Lupus Class Description 
I  Normal 
II A: Mesangial deposits 
B: Mesangial hypercellularity 
III Focal segmenal GN(<50%) 
IV Diffuse GN(>50%) 
V Membranous GN 
VI Advanced sclerosis 
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APPENDIX 4 -SAMPLE OF DATA RECORDING SHEET 
Num Age at 
presentation Sex 
Date of 
Presentation
last 
seen 
Months 
FU Status
Malar 
rash 
discoid 
lupus photosensi 
oral 
ulcers serositis arthritis renal haem CNS ANF comp dsDNA Sm Apl 
1 12 f 11/1/95 1/1/97 15 d 1 1 1 0 0 0 1 1 0 640 1 10 1 0
2 14 f 2/1/00 3/1/00 3 d 1 0 0 0 0 0 1 0 0 1280 2 0 1
3 15 f 7/1/94 1/1/02 91 u 0 0 0 1 1 0 1 1 0 640 1 640 0 0
4 15 f 7/1/89 7/1/03 169 k 2 0 0 2 0 0 2 1 1 1280 1 640 1 1
5 15 f 2/1/87 3/1/92 62 d 1 0 0 1 0 2 2 0 2 640 1 160 0 0
6 16 f 3/1/02 7/1/03 17 k 1 1 0 1 0 1 0 0 0 640 0 0 1 0
7 16 f 2/1/94 1/1/00 72 u 1 0 1 1 0 1 1 0 0 640 2 640 1 0
8 16 f 5/1/02 7/1/03 15 k 1 0 1 0 0 2 1 0 0 1280 1 10 1 0
9 16 f 5/1/98 9/1/00 28 d 0 0 0 0 0 0 1 1 0 640 2 80 0 1
10 16 f 4/1/96 6/1/03 87 d 1 0 0 2 0 0 2 1 0 640 1 0 1 0
11 16 f 8/1/9510/1/00 63 u 1 1 1 0 0 2 1 0 2 640 2 640 0 1
12 16 f 6/1/00 7/1/03 38 k 1 0 0 0 0 1 0 1 2 1280 1 640 1 0
13 17 f 5/1/92 1/1/01 104 d 1 0 0 1 0 0 1 1 0 640 1 640 0 0
14 17 f 5/1/95 7/1/03 99 k 1 2 1 1 0 1 2 1 0 160 2 160 0 1
15 17 f 6/1/94 7/1/03 110 k 0 0 0 0 0 2 2 1 0 640 1 0 1 0
16 17 f 8/1/00 6/1/01 11 u 1 0 0 1 0 0 0 1 1 640 2 640 0 0
17 17 f 5/1/9511/1/95 7 d 1 1 0 1 0 0 0 1 1 40 0 0 0 1
18 18 f 11/1/93 4/1/98 54 d 1 1 1 2 0 0 2 0 0 640 1 160 1 1
19 19 f 10/1/0011/1/00 3 u 1 0 0 0 0 0 0 1 0 640 0 0 1 0
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